Figure 6. Binding energies and interactions of TKIs to KIT 11^{Val555_Leu576del}/17^Asp820Gly mutations.

(a) Stereo views of IM, nilotinib, and sorafenib binding to KIT showing key hydrogen bonds formed with A599 and R684 in different models. (b) Binding energies of IM, SU, nilotinib, dasatinib, and sorafenib were estimated according docking TKIs to KIT mutants on exon 11^{Val555_Leu576del}/exon 17^Asp820Gly.